113 related articles for article (PubMed ID: 36893941)
1. Chelerythrine, a novel small molecule targeting IL-2, inhibits melanoma progression by blocking the interaction between IL-2 and its receptor.
Cho O; Lee JW; Kim HS; Jeong YJ; Heo TH
Life Sci; 2023 May; 320():121559. PubMed ID: 36893941
[TBL] [Abstract][Full Text] [Related]
2. Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma.
Cho O; Lee JW; Jeong YJ; Kim LK; Jung BK; Heo TH
Eur J Pharmacol; 2024 Jan; 962():176239. PubMed ID: 38043776
[TBL] [Abstract][Full Text] [Related]
3. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Lozano T; Villanueva L; Durántez M; Gorraiz M; Ruiz M; Belsúe V; Riezu-Boj JI; Hervás-Stubbs S; Oyarzábal J; Bandukwala H; Lourenço AR; Coffer PJ; Sarobe P; Prieto J; Casares N; Lasarte JJ
J Immunol; 2015 Oct; 195(7):3180-9. PubMed ID: 26324768
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis.
Feng T; Cao AT; Weaver CT; Elson CO; Cong Y
Gastroenterology; 2011 Jun; 140(7):2031-43. PubMed ID: 21419767
[TBL] [Abstract][Full Text] [Related]
7. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
8. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
9. Distepharinamide, a novel dimeric proaporphine alkaloid from Diploclisia glaucescens, inhibits the differentiation and proliferative expansion of CD4
Chen FY; Geng CA; Chou CK; Zheng JB; Yang Y; Wang YF; Li TZ; Li P; Chen JJ; Chen X
Phytomedicine; 2022 Dec; 107():154482. PubMed ID: 36202057
[TBL] [Abstract][Full Text] [Related]
10. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
11. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation.
Wang X; Wang W; Xu J; Le Q
Transplant Proc; 2013 Mar; 45(2):528-37. PubMed ID: 23267787
[TBL] [Abstract][Full Text] [Related]
12. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
13. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
14. Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells.
Lee H; Lee H; Kwon Y; Lee JH; Kim J; Shin MK; Kim SH; Bae H
J Immunol; 2010 Dec; 185(11):6698-705. PubMed ID: 21048105
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Fan K; Borden E; Yi T
J Interferon Cytokine Res; 2009 Aug; 29(8):451-60. PubMed ID: 19514839
[TBL] [Abstract][Full Text] [Related]
16. [Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice].
Jiao YM; Zhang L; Ge YY; Liang YJ; Yong W
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2011 Jun; 23(3):301-6. PubMed ID: 22164498
[TBL] [Abstract][Full Text] [Related]
17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
18. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.
Brandenburg S; Takahashi T; de la Rosa M; Janke M; Karsten G; Muzzulini T; Orinska Z; Bulfone-Paus S; Scheffold A
Eur J Immunol; 2008 Jun; 38(6):1643-53. PubMed ID: 18493984
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
Elpek KG; Yolcu ES; Franke DD; Lacelle C; Schabowsky RH; Shirwan H
J Immunol; 2007 Dec; 179(11):7295-304. PubMed ID: 18025172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
